|
1
|
Kim H, Eun JW, Lee H, Nam SW, Rhee H, Koh
KH and Kim H: Gene expression changes in patient-matched gastric
normal mucosa, adenomas, and carcinomas. Exp Mol Pathol.
90:201–209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Togo R, Ishihara K, Mabe K, Oizumi H,
Ogawa T, Kato M, Sakamoto N, Nakajima S, Asaka M and Haseyama M:
Preliminary study of automatic gastric cancer risk classification
from photofluorography. World J Gastrointest Oncol. 10:62–70. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Manzoni G, Marrelli D, Baiocchi GL,
Morgagni P, Saragoni L, Degiuli M, Donini A, Fumagalli U, Mazzei
MA, Pacelli F, et al: The Italian research group for gastric cancer
(GIRCG) guidelines for gastric cancer staging and treatment: 2015.
Gastric Cancer. 20:20–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brenner H: Long-term survival rates of
cancer patients achieved by the end of the 20th century: A period
analysis. Lancet. 360:1131–1135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Werner M, Becker KF, Keller G and Höfler
H: Gastric adenocarcinoma: Pathomorphology and molecular pathology.
J Cancer Res Clin Oncol. 127:207–216. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tahara E: Genetic pathways of two types of
gastric cancer. IARC Sci Publ. 157:327–349. 2004.
|
|
9
|
Wei Q, Wang YN, Liu HY, Yang J, Yang CY,
Liu M, Liu YF, Yang P and Liu ZH: The expression and role of
activin A and follistatin in heart failure rats after myocardial
infarction. Int J Cardiol. 168:2994–2997. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shibanuma M, Mashimo J, Mita A, Kuroki T
and Nose K: Cloning from a mouse osteoblastic cell line of a set of
transforming-growth-factor-beta 1-regulated genes, one of which
seems to encode a follistatin-related polypeptide. Eur J Biochem.
217:13–19. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sylva M, Moorman AF and van den Hoff MJ:
Follistatin-like 1 in vertebrate development. Birth Defects Res C
Embryo Today. 99:61–69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Prakash S, Borreguero LJJ, Sylva M, Flores
Ruiz L, Rezai F, Gunst QD, de la Pompa JL, Ruijter JM and van den
Hoff MJB: Deletion of Fstl1 (follistatin-like 1) from the
endocardial/endothelial lineage causes mitral valve disease.
Arterioscler Thromb Vasc Biol. 37:e116–e130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kawabata D, Tanaka M, Fujii T, Umehara H,
Fujita Y, Yoshifuji H, Mimori T and Ozaki S: Ameliorative effects
of follistatin-related protein/TSC-36/FSTL1 on joint inflammation
in a mouse model of arthritis. Arthritis Rheum. 50:660–668. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miyamae T, Marinov AD, Sowders D, Wilson
DC, Devlin J, Boudreau R, Robbins P and Hirsch R: Follistatin-like
protein-1 is a novel proinflammatory molecule. J Immunol.
177:4758–4762. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bae K, Park KE, Han J, Kim J, Kim K and
Yoon KA: Mitotic cell death caused by follistatin-like 1 inhibition
is associated with up-regulated Bim by inactivated Erk1/2 in human
lung cancer cells. Oncotarget. 7:18076–18084. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong Y, Geng Y, Li L, Li X, Yan X, Fang Y,
Li X, Dong S, Liu X, Li X, et al: Blocking follistatin-like 1
attenuates bleomycin-induced pulmonary fibrosis in mice. J Exp Med.
212:235–252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ouchi N, Oshima Y, Ohashi K, Higuchi A,
Ikegami C, Izumiya Y and Walsh K: Follistatin-like 1, a secreted
muscle protein, promotes endothelial cell function and
revascularization in ischemic tissue through a nitric-oxide
synthase-dependent mechanism. J Biol Chem. 283:32802–32811. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Geng Y, Dong Y, Yu M, Zhang L, Yan X, Sun
J, Qiao L, Geng H, Nakajima M, Furuichi T, et al: Follistatin-like
1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling
antagonist in controlling mouse lung development. Proc Natl Acad
Sci USA. 108:7058–7063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sylva M, Li VS, Buffing AA, van Es JH, van
den Born M, van der Velden S, Gunst Q, Koolstra JH, Moorman AF,
Clevers H and van den Hoff MJ: The BMP antagonist follistatin-like
1 is required for skeletal and lung organogenesis. PLoS One.
6:e226162011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu J, Qi X, Gong J, Yu M, Zhang F, Sha H
and Gao X: Fstl1 antagonizes BMP signaling and regulates ureter
development. PLoS One. 7:e325542012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murakami K, Tanaka M, Usui T, Kawabata D,
Shiomi A, Iguchi-Hashimoto M, Shimizu M, Yukawa N, Yoshifuji H,
Nojima T, et al: Follistatin-related protein/follistatin-like 1
evokes an innate immune response via CD14 and toll-like receptor 4.
FEBS Lett. 586:319–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou X, Xiao X, Huang T, Du C, Wang S, Mo
Y, Ma N, Murata M, Li B, Wen W, et al: Epigenetic inactivation of
follistatin-like 1 mediates tumor immune evasion in nasopharyngeal
carcinoma. Oncotarget. 7:16433–16444. 2016.PubMed/NCBI
|
|
23
|
Liu X, Liu Y, Li X, Zhao J, Geng Y and
Ning W: Follistatin like-1 (Fstl1) is required for the normal
formation of lung airway and vascular smooth muscle at birth. PLoS
One. 12:e01778992017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Y, Tan X, Liu W, Chen X, Hou X, Shen
D, Ding Y, Yin J, Wang L, Zhang H, et al: Follistatin-like protein
1 plays a tumor suppressor role in clear-cell renal cell carcinoma.
Chin J Cancer. 37:22018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin X, Nie E, Zhou X, Zeng A, Yu T, Zhi T,
Jiang K, Wang Y, Zhang J and You Y: Fstl1 promotes glioma growth
through the BMP4/Smad1/5/8 signaling pathway. Cell Physiol Biochem.
44:1616–1628. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ihle JN: The Stat family in cytokine
signaling. Curr Opin Cell Biol. 13:211–217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Son DJ, Jung YY, Park MH, Lee HL, Song MJ,
Yoo HS, Hwang DY, Han SB and Hong JT: Activated natural killer
cells mediate the suppressive effect of interleukin-4 on tumor
development via STAT6 activation in an atopic condition melanoma
model. Neoplasia. 19:537–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jayakumar A and Bothwell ALM: Stat6
promotes intestinal tumorigenesis in a mouse model of adenomatous
polyposis by expansion of MDSCs and inhibition of cytotoxic CD8
response. Neoplasia. 19:595–605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang H, Huang S, Wu S, Yin S, Tang A and
Wen W: Follistatin-like protein-1 upregulates dendritic cell-based
immunity in patients with nasopharyngeal carcinoma. J Interferon
Cytokine Res. 37:494–502. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hussain S, Kodavanti PP, Marshburg JD,
Janoshazi A, Marinakos SM, George M, Rice A, Wiesner MR and
Garantziotis S: Decreased uptake and enhanced mitochondrial
protection underlie reduced toxicity of nanoceria in human
monocyte-derived macrophages. J Biomed Nanotechnol. 12:2139–2150.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yadav V, Varshney P, Sultana S, Yadav J
and Saini N: Moxifloxacin and ciprofloxacin induces S-phase arrest
and augments apoptotic effects of cisplatin in human pancreatic
cancer cells via ERK activation. BMC Cancer. 15:5812015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyake T, Miyake T, Sakaguchi M, Nankai H,
Nakazawa T and Morishita R: Prevention of asthma exacerbation in a
mouse model by simultaneous inhibition of NF-κB and STAT6
activation using a chimeric decoy strategy. Mol Ther Nucleic Acids.
10:159–169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mimura K, The JL, Okayama H, Shiraishi K,
Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, et al:
PD-L1 expression is mainly regulated by interferon gamma associated
with JAK-STAT pathway in gastric cancer. Cancer Sci. 109:43–53.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shimasaki S, Koga M, Esch F, Cooksey K,
Mercado M, Koba A, Ueno N, Ying SY, Ling N and Guillemin R: Primary
structure of the human follistatin precursor and its genomic
organization. Proc Natl Acad Sci USA. 85:4218–4222. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ni X, Cao X, Wu Y and Wu J: FSTL1
suppresses tumor cell proliferation, invasion and survival in
non-small cell lung cancer. Oncol Rep. 39:13–20. 2018.PubMed/NCBI
|
|
37
|
Su S, Parris AB, Grossman G, Mohler JL,
Wang Z and Wilson EM: Up-regulation of follistatin-like 1 by the
androgen receptor and melanoma antigen-A11 in prostate cancer.
Prostate. 77:505–516. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hirsch R and Wilson DC: Follistatin-like
protein-1 as a biomarker for inflammatory disorders. US Patent
8,741,584. Filed February 4 2013; issued June 2 2014.
|
|
39
|
Binnemars-Postma K, Bansal R, Storm G and
Prakash J: Targeting the Stat6 pathway in tumor-associated
macrophages reduces tumor growth and metastatic niche formation in
breast cancer. Faseb J. 32:969–978. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pastuszak-Lewandoska D,
Domańska-Senderowska D, Kordiak J, Antczak A, Czarnecka KH,
Migdalska-Sęk M, Nawrot E, Kiszałkiewicz JM and Brzeziańska-Lasota
E: Immunoexpression analysis of selected JAK/STAT pathway molecules
in patients with non- small-cell lung cancer. Pol Arch Intern Med.
127:758–764. 2017.PubMed/NCBI
|
|
41
|
Qing T, Yamin Z, Guijie W, Yan J and
Zhongyang S: STAT6 silencing induces hepatocellular
carcinoma-derived cell apoptosis and growth inhibition by
decreasing the RANKL expression. Biomed Pharmacother. 92:1–6. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Leon-Cabrera SA, Molina-Guzman E,
Delgado-Ramirez YG, Vázquez-Sandoval A, Ledesma-Soto Y,
Pérez-Plasencia CG, Chirino YI, Delgado-Buenrostro NL,
Rodriguez-Sosa M, Vaca-Paniagua F, et al: Lack of STAT6 attenuates
inflammation and drives protection against early steps of
colitis-associated colon cancer. Cancer Immunol Res. 5:385–396.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu G, Shi W and Zheng H: Inhibition of
STAT6/anoctamin-1 activation suppresses proliferation and invasion
of gastric cancer cells. Cancer Biother Radiopharm. 33:3–7. 2018.
View Article : Google Scholar : PubMed/NCBI
|
